Vanderbilt-Ingram Cancer Center
Trial Pipeline
High-Resolution PET-CT Imaging for Surgical Margin Visualization
NCT06915454
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
NCT06819228
Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial
NCT06593106
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
NCT06105801
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
NCT06399640
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
NCT06016855
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
NCT06110572
A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules
NCT06074133
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
NCT05945875
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
NCT05901545
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT05770531
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
NCT05996432
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
NCT05501665
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
NCT05361720
Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan
NCT06482957
Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
NCT04506008
The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
NCT06701214
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT03932786
Inherited CAncer REgistry
NCT03231891
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
NCT02702310
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
NCT01205815
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT00899301
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
NCT00897117
Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
NCT06638398
Improving Care After Inherited Cancer Testing
NCT04763915
COVID-19 and Cancer Consortium Registry
NCT04354701
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
NCT03694249
Early Detection of Lung Cancer
NCT03181256
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
NCT01791478
Nashville Early Diagnosis Lung Cancer Project
NCT01475500
Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration
NCT04250194
Visually Enhanced Education About Prostate Cancer
NCT02846870
Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis
NCT02676752
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
NCT02672475
Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis
NCT02677883
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
NCT02493530
Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy
NCT02324881
Programs to Support You During Chemotherapy (Pro-You)
NCT02148406
ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients
NCT01901367
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
NCT01207895
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
NCT00987766
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT00984542
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
NCT00930930
Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
NCT00837876
Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants
NCT00899457
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
NCT00514020
Pain Control in Hospice Patients With Cancer-Related Pain
NCT00609297
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
NCT00896675
Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer
NCT00574145
Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer
NCT00897468
Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol
NCT01230515
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
NCT00897793
Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT00574366
Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
NCT00897650
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
NCT00666211
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
NCT00466687
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00416650
Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
NCT00647218
Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00006104
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 40 |
| Phase 3 | 1 |
| Phase 4 | 2 |
What the Pipeline for Vanderbilt-Ingram Cancer Center Shows
According to the ClinicalTrials.gov registry, Vanderbilt-Ingram Cancer Center is linked to 143 US clinical trials across every stage of research activity. Of those, 107 studies are currently recruiting — about 75% of the sponsor's indexed portfolio — and 29 are already marked complete, representing roughly 20% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Vanderbilt-Ingram Cancer Center reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 53 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Vanderbilt-Ingram Cancer Center is Lung Cancer with 10 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.